Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15338545 | 1.00 | BACE1 (0.58) | BACE1BACE2 | |
| SCHEMBL6918319 | 1.00 | BACE1 (0.58) | BACE1BACE2 | |
| SCHEMBL15225050 | 1.00 | BACE1 (0.58) | BACE1BACE2 | |
| SCHEMBL11967148 | 0.87 | BACE1 (0.67) | BACE1BACE2 | |
| SCHEMBL15241656 | 0.87 | BACE1 (0.67) | BACE1BACE2 | |
| SCHEMBL11982781 | 0.87 | BACE1 (0.67) | BACE1BACE2 | |
| SCHEMBL11967192 | 0.87 | BACE1 (0.67) | BACE1BACE2 | |
| SCHEMBL6917160 | 0.87 | BACE1 (0.67) | BACE1BACE2 | |
| SCHEMBL15241663 | 0.86 | BACE1 (0.66) | BACE1BACE2 | |
| SCHEMBL11967139 | 0.82 | BACE1 (0.60) | BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202804-A1 | FUSED AMINODIHYDRO-OXAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-08-09 | — | — | US | disclosed |
| WO-2011009898-A1 | FUSED AMINODIHYDRO-OXAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD (JP) | 2011-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202804-A1 | FUSED AMINODIHYDRO-OXAZINE DERIVATIVES | BACE1, APP, BACE2 | BACE1 1/4885BACE2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.